Proquin Xr is a drug owned by Depomed Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 20, 2020. Details of Proquin Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(4 years ago) |
Expired
|
| US6340475 | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(8 years ago) |
Expired
|
| US6635280 | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(8 years ago) |
Expired
|
| US5972389 | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
Sep, 2016
(8 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Proquin Xr and ongoing litigations to help you estimate the early arrival of Proquin Xr generic.
Proquin Xr's Litigations
Proquin Xr been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 17, 2014, against patent number US6635280. The petitioner Endo Pharmaceutical Inc. et al., challenged the validity of this patent, with Depomed, Inc. as the respondent. Click below to track the latest information on how companies are challenging Proquin Xr's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6340475 | April, 2014 |
Final Written Decision
(21 Sep, 2015) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Final Written Decision
(21 Sep, 2015) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6340475 | January, 2014 |
FWD Entered
(08 Jul, 2015) | Depomed, Inc. | Purdue Pharma L.P. |
| US6635280 | January, 2014 |
FWD Entered
(08 Jul, 2015) | DepoMed, Inc. | Purdue Pharma L.P. |
| US6340475 | April, 2014 |
Institution Denied
(29 Sep, 2014) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Institution Denied
(29 Sep, 2014) | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US patents provide insights into the exclusivity only within the United States, but Proquin Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Proquin Xr's family patents as well as insights into ongoing legal events on those patents.
Proquin Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Proquin Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 20, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Proquin Xr Generic API suppliers:
Ciprofloxacin Hydrochloride is the generic name for the brand Proquin Xr. 27 different companies have already filed for the generic of Proquin Xr, with Rising having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Proquin Xr's generic
Alternative Brands for Proquin Xr
Proquin Xr which is used for treating uncomplicated urinary tract infections., has several other brand drugs using the same active ingredient (Ciprofloxacin Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ciprofloxacin Hydrochloride, Proquin Xr's active ingredient. Check the complete list of approved generic manufacturers for Proquin Xr
About Proquin Xr
Proquin Xr is a drug owned by Depomed Inc. It is used for treating uncomplicated urinary tract infections. Proquin Xr uses Ciprofloxacin Hydrochloride as an active ingredient. Proquin Xr was launched by Depomed Inc in 2005.
Approval Date:
Proquin Xr was approved by FDA for market use on 19 May, 2005.
Active Ingredient:
Proquin Xr uses Ciprofloxacin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Ciprofloxacin Hydrochloride ingredient
Treatment:
Proquin Xr is used for treating uncomplicated urinary tract infections.
Dosage:
Proquin Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 500MG BASE | TABLET, EXTENDED RELEASE | Discontinued | ORAL |